675 West Kendall Street
About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene editing platform. CRISPR is a revolutionary technology that allows for precise, directed changes to genomic DNA. The Company’s multi-disciplinary team of world-class researchers and drug developers is working on a number of wholly-owned programs to treat serious diseases with high unmet need.
Founders: Rodger Novak, Emmanuelle Charpentier, Shaun Foy
Scientific Founders: Chad Cowan, Daniel Anderson, Stephen Elledge, Craig Mello, Matthew Porteus
CEO and Co-founder: Rodger Novak
CFO: Marc Becker
CSO (Scientific): Sven Ante (Bill) Lundberg
Please click here for CRISPR Therapeutics job opportunities.
FOLLOW CRISPR THERAPEUTICS:
Tweets by CRISPR
79 articles with CRISPR Therapeutics
CRISPR Therapeutics and Vertex Announce Progress in Clinical Development Programs for the Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001
CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reviewed recent progress in the clinical development programs for CTX001, an investigational, autologous, CRISPR/Cas9 gene-edited hematopoietic stem cell therapy being evaluated for patients suffering from severe hemoglobinopathies.
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
This year has been a strong one for biotech initial public offerings (IPO). According to the Wall Street Journal, as of mid-October, 55 biotech companies had raised $5.75 billion.
10/31/2018It may not have always felt like it, but biotech has been in a bull market mode over the past two-and-a-half years, ever since the iShares Biotechnology Index (IBB) bottomed out at $80.01 on February 9, 2016.
Synthego Snags $110 Million in Series C to Advance Vision of Making CRISPR Technology More Available
10/23/2018Genome engineering company Synthego received an infusion of $110 million from a Series C financing round led by Peter Thiel’s Founders Fund. The funds will be used to accelerate the company’s vision to make CRISPR technology more accessible to researchers.
In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.
CRISPR Therapeutics today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer, will present at the Chardan Genetic Medicines Conference on Tuesday, October 9, 2018 at 11:30 am ET.
CRISPR Therapeutics and ViaCyte are collaborating to discover, develop and commercialize a gene-edited allogeneic stem cell therapy or therapies for diabetes.
CRISPR pioneer Jennifer Doudna has set up shop in San Francisco’s Gladstone Institutes. Doudna, a UC Berkley professor credited with the co-discovery of CRISPR-Cas9 genome editing technique, will focus on the development of new ways to implement the gene-editing technique for disease treatment.
As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.
CRISPR, the gene editing technique that promises designer babies, to end to all disease as we know it, and biohacking where individuals could change their own genome to include that of fluorescent jellyfish or lobster claws, seems to have more problems than originally thought.
Shares of CRISPR Therapeutics (-8 percent), Editas Medicines (-5 percent) and Intellia Therapeutics (-6.7 percent) are all plunging following the release of a report that claimed CRISPR-Cas9 gene editing may cause some dangerous side effects.
Now, two studies published in Nature Medicine suggest that CRISPR may lead to cancer unintentionally.
Shares of CRISPR Therapeutics plunged dramatically Wednesday after the U.S. Food and Drug Administration placed a clinical hold on a planned sickle cell disease treatment the company was in the process of developing with Vertex Pharmaceuticals.
All that is lacking from the likely drama surrounding patent battles over CRISPR technology in the U.S. Court of Appeals today is Michael Buffer’s cry of “Let’s get ready to rumble.”
Mammoth Biosciences, based in San Francisco, has officially launched to develop CRISPR technology for clinical diagnostics.
Bluebird bio announced interim data from two different two-year clinical trials of LentiGlobin gene therapy for transfusion-dependent beta-thalassemia (TDT).
The plan is to treat patients with beta thalassemia, a blood disorder that decreases the production of hemoglobin, the iron-containing protein in red blood cells that carries oxygen.
Going forward, Dr. Lundberg will serve as a Senior Advisor to the Company and has been named Head of CRISPR's Scientific Advisory Board.
A look at three small biotech companies that appear to be leading the CRISPR race.